Search

Displaying results 5701 - 5710 of 7479 in total
  1. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was...

  2. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous...

  3. Drug

    Vosilasarm

    go.drugbank.com/drugs/DB13939
    Investigational

    RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.

  4. Drug

    Stypocaulon scoparium

    go.drugbank.com/drugs/DB14260
    Investigational

    It is not an approved drug.

  5. Drug

    Arnica montana

    go.drugbank.com/drugs/DB14297
    Investigational

    It is not an approved drug.

  6. Drug

    Chicory leaf

    go.drugbank.com/drugs/DB14376
    Investigational

    It is not an approved drug.

    Synonyms: Ju Ju
  7. Drug

    Palm oil

    go.drugbank.com/drugs/DB14377
    Investigational

    It is not an approved drug.

  8. Drug

    ISIS 104838

    go.drugbank.com/drugs/DB16201
    Investigational

    ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

  9. Drug

    PRX-OTC

    go.drugbank.com/drugs/DB17680
    Experimental

    PRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.

  10. Drug

    SPL23-2

    go.drugbank.com/drugs/DB17866
    Experimental

    SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.[L46767]